$APLS
Apellis Pharmaceuticals, Inc. Stock $apls

$apls Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000156459022007606 Filed on February 28, 2022

Income Statement

Concept	2021	2020 Q4	2020
Revenue	$66.56M	$250.0M	$250.6M
YoY Change	-73.44%
Cost Of Revenue	$5.200M	$25.10M	$25.10M
YoY Change	-79.28%
Gross Profit	$61.36M	$225.0M	$225.6M
YoY Change	-72.8%
Gross Profit Margin	92.19%	90.0%	90.01%
Selling, General & Admin	$284.5M	$65.80M	$215.7M
YoY Change	31.87%	139.27%	221.94%
% of Gross Profit	463.55%	29.24%	95.61%
Research & Development	$345.9M	$29.00M	$299.9M
YoY Change	15.32%	-63.06%	35.73%
% of Gross Profit	563.64%	12.89%	132.94%
Depreciation & Amortization	$1.379M	$270.0K	$637.0K
YoY Change	116.48%	200.0%	165.42%
% of Gross Profit	2.25%	0.12%	0.28%
Operating Expenses	$602.8M	$94.80M	$464.4M
YoY Change	29.82%	-10.48%	61.23%
Operating Profit	-$536.3M	$130.1M	-$213.7M
YoY Change	150.92%	-222.82%	-25.79%
Interest Expense	-$110.5M	-$49.50M	-$128.8M
YoY Change	-14.21%	587.5%	758.67%
% of Operating Profit		-38.04%
Other Income/Expense, Net	$1.362M	-$500.0K	-$501.0K
YoY Change	-371.86%	400.0%	186.29%
Pretax Income	-$746.0M	$80.10M	-$343.0M
YoY Change	117.47%	-170.76%	12.58%
Income Tax	$352.0K	$1.800M	$1.845M
% Of Pretax Income		2.25%
Net Earnings	-$746.4M	$78.27M	-$344.9M
YoY Change	116.41%	-169.13%	13.18%
Net Earnings / Revenue	-1121.27%	31.31%	-137.59%
Basic Earnings Per Share	-$8.84	$1.03	-$4.59
Diluted Earnings Per Share	-$8.841M	$0.93	-$4.586M
COMMON SHARES
Basic Shares Outstanding	84.42M		75.16M
Diluted Shares Outstanding	84.42M		75.16M

Balance Sheet

Concept	2021	2020 Q4	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$700.6M	$877.6M	$877.6M
YoY Change	-20.17%	149.32%	149.32%
Cash & Equivalents	$640.2M	$565.8M	$565.8M
Short-Term Investments	$60.36M	$311.9M	$311.9M
Other Short-Term Assets	$97.11M	$26.88M	$39.50M
YoY Change	145.84%	1954.89%	87.2%
Inventory	$16.29M	$0.00
Prepaid Expenses		$11.40M
Receivables	$10.10M
Other Receivables	$0.00
Total Short-Term Assets	$824.0M	$917.2M	$917.2M
YoY Change	-10.16%	145.83%	145.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.08M	$6.803M	$24.50M
YoY Change	6.44%	311.06%	55.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$31.64M	$18.86M	$18.90M
YoY Change	67.41%	4797.4%	4625.0%
Total Long-Term Assets	$57.72M	$43.38M	$43.40M
YoY Change	32.99%	168.59%	169.57%
TOTAL ASSETS
Total Short-Term Assets	$824.0M	$917.2M	$917.2M
Total Long-Term Assets	$57.72M	$43.38M	$43.40M
Total Assets	$881.8M	$960.6M	$960.6M
YoY Change	-8.21%	146.78%	146.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.91M	$8.477M	$8.500M
YoY Change	98.93%	1.39%	1.19%
Accrued Expenses	$107.4M	$111.9M	$115.6M
YoY Change	-7.13%	104.32%	101.39%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.584M	$4.200M	$4.200M
YoY Change	80.57%
Total Short-Term Liabilities	$131.8M	$128.3M	$128.3M
YoY Change	2.76%	95.17%	94.98%
LONG-TERM LIABILITIES
Long-Term Debt	$534.2M	$358.8M	$358.8M
YoY Change	48.88%	151.61%	151.61%
Other Long-Term Liabilities	$17.08M	$268.9M	$268.9M
YoY Change	-93.65%	83.3%	83.3%
Total Long-Term Liabilities	$551.3M	$627.7M	$627.7M
YoY Change	-12.18%	116.97%	116.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$131.8M	$128.3M	$128.3M
Total Long-Term Liabilities	$551.3M	$627.7M	$627.7M
Total Liabilities	$683.1M	$756.0M	$756.0M
YoY Change	-9.64%	112.95%	112.96%
SHAREHOLDERS EQUITY
Retained Earnings		-$926.3M
YoY Change		59.31%
Common Stock		$8.000K
YoY Change		33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$198.7M	$204.6M	$204.6M
YoY Change
Total Liabilities & Shareholders Equity	$881.8M	$960.6M	$960.6M
YoY Change	-8.21%	146.78%	146.81%

Cashflow Statement

Concept	2021	2020 Q4	2020
OPERATING ACTIVITIES
Net Income	-$746.4M	$78.27M	-$344.9M
YoY Change	116.41%	-169.13%	13.18%
Depreciation, Depletion And Amortization	$1.379M	$270.0K	$637.0K
YoY Change	116.48%	200.0%	165.42%
Cash From Operating Activities	-$563.1M	$142.0M	-$160.5M
YoY Change	250.88%	-272.98%	-23.99%
INVESTING ACTIVITIES
Capital Expenditures	$1.103M	-$710.0K	$5.422M
YoY Change	-79.66%	373.33%	220.26%
Acquisitions
YoY Change
Other Investing Activities	$248.7M	$620.0K	-$311.6M
YoY Change	-179.83%
Cash From Investing Activities	$247.6M	-$90.00K	-$317.0M
YoY Change	-178.12%	-40.0%	18623.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$380.4M		$381.4M
YoY Change	-0.28%		248.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	392.2M	6.320M	692.2M
YoY Change	-43.33%	2909.52%	78.15%
NET CHANGE
Cash From Operating Activities	-563.1M	142.0M	-160.5M
Cash From Investing Activities	247.6M	-90.00K	-317.0M
Cash From Financing Activities	392.2M	6.320M	692.2M
Net Change In Cash	74.71M	148.2M	215.1M
YoY Change	-65.26%	-280.7%	22.39%
FREE CASH FLOW
Cash From Operating Activities	-$563.1M	$142.0M	-$160.5M
Capital Expenditures	$1.103M	-$710.0K	$5.422M
Free Cash Flow	-$564.2M	$142.7M	-$165.9M
YoY Change	240.08%	-274.16%	-22.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2019	us-gaap	Defined Contribution Plan Tax Status Extensible List DefinedContributionPlanTaxStatusExtensibleList	http://fasb.org/us-gaap/2021-01-31#QualifiedPlanMember
CY2020	us-gaap	Defined Contribution Plan Tax Status Extensible List DefinedContributionPlanTaxStatusExtensibleList	http://fasb.org/us-gaap/2021-01-31#QualifiedPlanMember
CY2021	us-gaap	Defined Contribution Plan Tax Status Extensible List DefinedContributionPlanTaxStatusExtensibleList	http://fasb.org/us-gaap/2021-01-31#QualifiedPlanMember
CY2021	apls	Defined Contribution Plan Eligibility Criteria Minimum Age Of Full Time Employees DefinedContributionPlanEligibilityCriteriaMinimumAgeOfFullTimeEmployees	P21Y
CY2021	apls	Net Operating Loss Carryforward Period NetOperatingLossCarryforwardPeriod	P3Y
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	apls	Accounting Standards Update Description AccountingStandardsUpdateDescription	ASU 2020-06
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M28D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M2D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M28D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y5M4D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0041
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0032
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0142
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0134
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0176
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0256
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.711
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.844
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.026
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.744
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.878
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.112
CY2021	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	640192000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	565779000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	60358000
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	311869000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10103000
CY2021Q4	us-gaap	Inventory Net InventoryNet	16286000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	24868000
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11400000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	70677000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	26878000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	824047000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	917192000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19901000
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1563000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1266000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17719000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6177000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6803000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	31640000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18855000
CY2021Q4	us-gaap	Assets Assets	881765000
CY2020Q4	us-gaap	Assets Assets	960569000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	16909000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8477000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	103239000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	111935000
CY2021Q4	apls	Development Liability Current DevelopmentLiabilityCurrent	7584000
CY2020Q4	apls	Development Derivative Liabilities Current DevelopmentDerivativeLiabilitiesCurrent	4230000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4115000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3685000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	131847000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	128327000
CY2021Q4	apls	Development Liability Noncurrent DevelopmentLiabilityNoncurrent	345151000
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	189024000
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	358830000
CY2020Q4	apls	Development Derivative Liabilities Noncurrent DevelopmentDerivativeLiabilitiesNoncurrent	253638000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17081000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15217000
CY2021Q4	us-gaap	Liabilities Liabilities	683103000
CY2020Q4	us-gaap	Liabilities Liabilities	756012000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97524000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97524000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	76130000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	76130000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	10000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	8000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1857430000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	299921000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	220969000
CY2021	apls	Cost Of Research Collaboration CostOfResearchCollaboration	75000000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	176771000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	139401000
CY2021	us-gaap	Operating Expenses OperatingExpenses	602840000
CY2020	us-gaap	Operating Expenses OperatingExpenses	464372000
CY2019	us-gaap	Operating Expenses OperatingExpenses	288015000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-536277000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-213726000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-288015000
CY2021	apls	Loss On Conversion Of Debt LossOnConversionOfDebt	100589000
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-103029000
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-14839000
CY2019	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	5108000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-746354000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-344874000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-304707000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1131013000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2090000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-117000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1656688000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-926347000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	198662000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	204557000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	881765000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	960569000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	66563000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	250646000
CY2021	apls	Operating Cost Of Sales OperatingCostOfSales	200000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	345869000
CY2021	apls	License Expense LicenseExpense	5000000
CY2020	apls	License Expense LicenseExpense	25050000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	67046000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1501000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-97675000
CY2021	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	418000
CY2020	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	4164000
CY2020	apls	Interest Expense Nonoperating InterestExpenseNonoperating	29937000
CY2019	apls	Interest Expense Nonoperating InterestExpenseNonoperating	5285000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-175000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-746002000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-343029000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-304707000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	352000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1845000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	45000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-31000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-31000
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	84421000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	160973000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	109581000
CY2019	apls	Stock Issued During Period Value Stock Options Or Warrant Exercised StockIssuedDuringPeriodValueStockOptionsOrWarrantExercised	3129000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	72520000
CY2019	apls	Adjustments To Additional Paid In Capital Purchase Of Capped Call Transactions And Associated Costs AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsAndAssociatedCosts	-28380000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	381423000
CY2020	apls	Stock Issued During Period Value Stock Options Or Warrant Exercised StockIssuedDuringPeriodValueStockOptionsOrWarrantExercised	9418000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	120485000
CY2020Q4	apls	Development Derivative Liabilities Gross DevelopmentDerivativeLiabilitiesGross	257868000
CY2020	apls	Adjustments To Additional Paid In Capital Purchase Of Capped Call Transactions And Associated Costs AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsAndAssociatedCosts	-43112000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	45376000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1575000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-8000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-344874000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	45000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	204557000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	380362000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14691000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	421093000
CY2021	apls	Adjustments To Additional Paid In Capital Forfeiture Of Accrued Interest In Exchange Of Convertible Notes AdjustmentsToAdditionalPaidInCapitalForfeitureOfAccruedInterestInExchangeOfConvertibleNotes	4171000
CY2021	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-1788000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2970000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-746354000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1982000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	198662000
CY2020	us-gaap	Profit Loss ProfitLoss	-344874000
CY2019	us-gaap	Profit Loss ProfitLoss	-304707000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	70667000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	45376000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	21144000
CY2021	apls	Loss On Conversion Of Debt LossOnConversionOfDebt	100589000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1501000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-97675000
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-103029000
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-14839000
CY2021	apls	Forfeiture Of Accrued Interest In Exchange Of Convertible Notes ForfeitureOfAccruedInterestInExchangeOfConvertibleNotes	4171000
CY2021	us-gaap	Depreciation Depreciation	1379000
CY2020	us-gaap	Depreciation Depreciation	637000
CY2019	us-gaap	Depreciation Depreciation	240000
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	52000
CY2021	apls	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	113000
CY2020	apls	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	222000
CY2019	apls	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	356000
CY2019	apls	Amortization Of Term Loan Facility Discounts AmortizationOfTermLoanFacilityDiscounts	104000
CY2021	apls	Amortization Of Discounts For Convertible Notes Net Of Financing Costs AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts	964000
CY2020	apls	Amortization Of Discounts For Convertible Notes Net Of Financing Costs AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts	15536000
CY2019	apls	Amortization Of Discounts For Convertible Notes Net Of Financing Costs AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts	2186000
CY2021	apls	Accretion Of Discount To Development Liability AccretionOfDiscountToDevelopmentLiability	1192000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10103000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	16317000
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	13487000
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-8738000
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-4531000
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	40928000
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	26284000
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-287000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	12782000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	17860000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	323000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10487000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-54000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1641000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-10392000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	381423000
CY2021	apls	Proceeds From Payments For Development Derivative Liability ProceedsFromPaymentsForDevelopmentDerivativeLiability	-4000000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	351985000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	351985000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	1266000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	641755000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	567045000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	10265000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2016000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	359000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5422000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1693000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	171281000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	879067000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	420000000
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	567500000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	247616000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	55046000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	50454000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-158000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-563126000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-160488000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-211135000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1103000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-316989000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1693000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	380363000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	109581000
CY2020	apls	Proceeds From Payments For Development Derivative Liability ProceedsFromPaymentsForDevelopmentDerivativeLiability	20000000
CY2019	apls	Proceeds From Payments For Development Derivative Liability ProceedsFromPaymentsForDevelopmentDerivativeLiability	120000000
CY2020	apls	Payments For Capped Call Transactions And Associated Costs PaymentsForCappedCallTransactionsAndAssociatedCosts	43112000
CY2019	apls	Payments For Capped Call Transactions And Associated Costs PaymentsForCappedCallTransactionsAndAssociatedCosts	28380000
CY2020	apls	Proceeds From Issuance Of Convertible Notes Net Of Issuance Costs ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCosts	322874000
CY2019	apls	Proceeds From Issuance Of Convertible Notes Net Of Issuance Costs ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCosts	212912000
CY2021	apls	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	14691000
CY2020	apls	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	9418000
CY2019	apls	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	3129000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2970000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1575000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1788000
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7000000
CY2019	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	21701000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	392236000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	692178000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	388541000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	74710000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	215060000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	175717000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	567045000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	351985000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	176268000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	641755000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	567045000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	640192000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	565779000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	1563000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	351985000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	12929000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	987000
CY2020	apls	Equity Component Of Convertible Notes EquityComponentOfConvertibleNotes	120485000
CY2019	apls	Equity Component Of Convertible Notes EquityComponentOfConvertibleNotes	72520000
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	328017000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Organization and Operations </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Apellis Pharmaceuticals, Inc. (the “Company”) is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was incorporated in September 2009 under the laws of the State of Delaware. The Company’s principal executive offices are located in Waltham, Massachusetts. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s operations since inception have been limited to organizing and staffing the Company, acquiring rights to product candidates, business planning, raising capital, developing its product candidates, and commercializing EMPAVELI (pegcetacoplan) for the treatment of paroxysmal nocturnal hemogobinuria, or PNH. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common in the biotechnology industry including, but not limited to, raising additional capital, development by its competitors of new technological innovations, its ability to successfully complete preclinical and clinical development of product candidates and receive timely regulatory approval of products, market acceptance of the Company’s products, protection of proprietary technology, healthcare cost containment initiatives, and compliance with governmental regulations, including those of the U.S. Food and Drug Administration (“FDA”). Additionally, the Company is subject to risks arising from the Coronavirus Disease 2019 (COVID-19) pandemic, which could have adverse effects upon its business and operations, including on its ability to initiate, conduct and complete clinical trials, and could disrupt regulatory activities.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.4%;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Adoption of ASU 2020-06 Debt – Debt with Conversion and Other Options (Subtopic 470-20)</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-weight:bold;;font-size:9pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2021, the Company early adopted ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) which reduces complexity in applying GAAP to certain financial instruments with characteristics of liability and equity. The ASU removes the guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The ASU further revises the guidance to require entities to calculate diluted earnings per share for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted earnings per share when an instrument may be settled in cash or shares. The impact of the adoption of the statement increased net debt outstanding and decreased net equity by $149.7 million as of January 1, 2021. Of the $149.7 million decrease to net equity, $16.0 million was recorded to retained earnings. See Note 8, Long Term Debt for additional information.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaboration and License Agreement </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 27, 2020, the Company and its wholly-owned subsidiaries Apellis Switzerland GmbH and APL DEL Holdings, LLC entered into a Collaboration and License Agreement with Sobi, concerning the development and commercialization of pegcetacoplan and specified other structurally and functionally similar compstatin analogues or derivatives for use systemically or for local non-ophthalmological administration (collectively referred to as the “Licensed Products”). </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the collaboration agreement, the Company granted Sobi an exclusive (subject to certain retained rights of the Company), sublicensable license of certain patent rights and know-how to develop and commercialize Licensed Products in all countries outside of the United States. The Company retained the right to commercialize Licensed Products in the United States, and, subject to specified limitations, to develop Licensed Products worldwide for commercialization in the United States. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sobi paid the Company an upfront payment of $250.0 million in November 2020 and has agreed to pay up to an aggregate of $915.0 million upon the achievement of specified one-time regulatory and commercial milestone events, and to reimburse the Company for up to $80.0 million in development costs. The Company will also be entitled to receive tiered, double-digit royalties (ranging from high teens to high twenties) on sales of Licensed Products outside of the United States, subject to customary deductions and third-party payment obligations, until the latest to occur of: (i) expiration of the last-to-expire of specified licensed patent rights; (ii) expiration of regulatory exclusivity; and (iii) ten (10) years after the first commercial sale of the applicable Licensed Product, in each case on a Licensed Product-by-Licensed Product and country-by-country basis. Under the collaboration agreement, the Company remains responsible for its license fee obligations (including royalty obligations) to the University of Pennsylvania as a licensor of the Company and for its payment obligations to SFJ Pharmaceuticals. <span style="Background-color:#FFFFFF;color:#000000;">See note 13, License and Collaboration Agreements, for further discussion related to the Sobi collaboration agreemen</span>t. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:3.4%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Notes Exchange</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="color:#000000;"> </span> <span style="margin-left:36pt;"/><span style="color:#000000;">On January 6, 2021, the Company entered into separate, privately negotiated exchange agreements with certain holders of its convertible notes issued in September 2019 (the “2019 Convertible Notes”). Under the terms of these exchange agreements, the holders exchanged approximately $126.1 million in aggregate principal amount of 2019 Convertible Notes held by them for an aggregate of 3,906,869 shares of common stock. The Company also issued 69,491 shares for settlement of issuance costs paid to the Company’s advisor. The Company recognized a total loss on conversion of debt in consolidated statement of operations of $39.5 million.</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the Company entered into separate, privately negotiated exchange agreements to modify the conversion terms with certain holders of the 2019 Convertible Notes and the 2020 Convertible Notes issued in May 2020 (the “2020 Convertible Notes”, and together with the 2019 Convertible Notes, the “Convertible Notes”). Under the terms of these exchange agreements, the holders exchanged approximately $201.1 million in aggregate principal amount of Convertible Notes held by them for an aggregate of 5,992,217 shares of common stock issued by the Company. The Company also has agreed to issue 78,419 shares for settlement of issuance costs paid to the Company’s advisor. The Company recognized a total loss on conversion of $61.1 million during the year ended December 31, 2021. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The conditional conversion feature of the Convertible Notes was triggered as of June 30, 2021, and so the Convertible Notes were convertible at the option of the holders, in whole or in part, between July 1, 2021 and September 30, 2021. From July 1, 2021, we had received conversion requests for the Convertible Notes for the conversion of approximately $0.7 million in aggregate principal amount of Convertible Notes. We issued an aggregate of 18,775 shares of common stock to settle these conversions requests in October 2021</span>. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company held in treasury Convertible Notes in the principal amount of $327.2 million which notes have not been cancelled. See Note 8, Long Term Debt for additional information.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:3.4%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Capped Call Transactions </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 6, 2020, concurrently with the pricing of the 2020 Convertible Notes, the Company entered into capped call transactions with two counterparties. The capped call transactions are expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of the 2020 Convertible Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted 2020 Convertible Notes, as the case may be, in the event that the market price per share of the Company’s common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which is initially $39.4625 (the conversion price of the 2020 Convertible Notes) and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of such 2020 Convertible Notes. <span style="font-weight:bold;font-style:italic;"> </span></p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:3.4%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Follow-on Public Offerings</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 18, 2021, the Company issued and sold 10,062,500 shares of its common stock at a price per share to the public of $40.00 in a follow-on public offering including an additional 1,312,500 shares of its common stock that were sold at the follow-on public offering price of $40.00 per share pursuant to the underwriters’ agreement in full exercise of their option to purchase additional shares of common stock. The Company received net proceeds of approximately $380.4 million after deducting underwriting discounts and commissions of approximately $22.1 million and offering costs of $0.6 million for these transactions.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 13, 2020, the Company issued and sold 10,925,000 shares of its common stock at a price per share to the public of $37.00 in a follow-on public offering including an additional 1,425,000 shares of its common stock that were sold at the follow-on public offering price of $37.00 per share pursuant to the underwriters’ <span style="color:#000000;">agreement</span> in full exercise of their option to purchase additional shares of common stock. The Company received net proceeds of approximately $381.4 million after deducting underwriting discounts and commissions of approximately $22.2 million and offering costs of $0.5 million for these transactions. </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:3.4%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-weight:bold;font-style:italic;color:#000000;">Liquidity and Going Concern </span></p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The accompanying consolidated financial statements have been prepared on the basis of the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of February 28, 2022, the date of issuance of these consolidated financial statements, the Company believes that its cash and cash equivalents and marketable securities as of December 31, 2021 of $700.6 million, will be sufficient to fund its operations and capital expenditures for at least the next twelve months from the date of issuance of these consolidated financial statements. The Company’s future viability beyond that point is dependent on its ability to raise additional capital to finance its operations.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to other life science companies in the development stage including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing, and compliance with FDA and other government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability. Management’s plans in order to meet its short-term and longer-term operating cash flow requirements include obtaining additional funding. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are uncertainties associated with the Company’s ability to (1) obtain additional debt or equity financing on terms that are favorable to the Company, (2) enter into collaborative agreements with strategic partners, and (3) succeed in its future operations. If the Company is not able to obtain the required funding for its operations or is not able to obtain funding on terms that are favorable to the Company, it could be forced to delay, reduce or eliminate its research and development programs or future commercialization efforts and its business could be materially harmed. </p>
CY2021Q4	apls	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	700600000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-bottom:0pt;margin-top:18pt;margin-left:1.69%;text-indent:1.71%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: development derivative liability, accrued expenses, prepaid expenses, convertible debt and taxes. </p>
CY2021Q4	apls	Obsolete Inventory ObsoleteInventory	0
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:18pt;text-indent:3.4%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents are the only financial instruments that potentially subject the Company to concentrations of credit risk. <span style="color:#000000;">Cash and cash equivalents are held at financial institutions in the United States, Netherlands, Switzerland, Australia, Ireland and Germany. The Company is exposed to credit risk in the event of default by the financial institution to the extent that cash and cash equivalent balances recorded in the balance sheets are in excess of the amounts that are insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses on its deposits since inception, and management believes that minimal credit risk exists with respect to these financial institutions. </span> </p>
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	10100000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	5700000
CY2020Q4	us-gaap	Inventory Net InventoryNet	0
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10100000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	200000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	500000
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11815000
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9526000
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7291000
CY2020Q4	apls	Development Derivative Liabilities Gross DevelopmentDerivativeLiabilitiesGross	257868000
CY2019Q4	apls	Development Derivative Liabilities Gross DevelopmentDerivativeLiabilitiesGross	134839000
CY2020	apls	Minimum Payment Of Additional Funding Amount MinimumPaymentOfAdditionalFundingAmount	20000000
CY2021	apls	Minimum Payment Of Additional Funding Amount MinimumPaymentOfAdditionalFundingAmount	-4000000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-97675000
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-103029000
CY2021	apls	Reclassification To Development Liability ReclassificationToDevelopmentLiability	351543000
CY2021Q4	apls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	35217000
CY2020Q4	apls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	47879000
CY2021Q4	apls	Accrued Cost Of Research Collaborations Current AccruedCostOfResearchCollaborationsCurrent	25000000
CY2021Q4	apls	Accrued License Fees Current AccruedLicenseFeesCurrent	5000000
CY2020Q4	apls	Accrued License Fees Current AccruedLicenseFeesCurrent	25050000
CY2021Q4	apls	Accrued Payroll Liabilities Current AccruedPayrollLiabilitiesCurrent	25212000
CY2020Q4	apls	Accrued Payroll Liabilities Current AccruedPayrollLiabilitiesCurrent	22896000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12810000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	16110000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	103239000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	111935000
CY2021Q4	apls	Prepaid Research And Development Cost Current PrepaidResearchAndDevelopmentCostCurrent	12000000.0
CY2020Q4	apls	Prepaid Research And Development Cost Current PrepaidResearchAndDevelopmentCostCurrent	8000000.0
CY2021	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company enters into lease agreements with terms generally ranging from 2-7 years. Some of the Company’s lease agreements include Company options to extend the lease on a month-to-month basis or for set periods for up to five years. Many leases also include options to terminate the leases within one year or per other contractual terms. Renewal and termination options were generally not included in the lease term for the Company’s existing operating leases.
CY2021	apls	Lessee Operating Lease Maximum Term Of Options To Terminate Lease LesseeOperatingLeaseMaximumTermOfOptionsToTerminateLease	P1Y
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19901000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17719000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21196000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	18902000
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0771
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0774
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	5600000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	4400000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	2400000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	5989000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	4732000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	2013000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5675000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7237000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	10201000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5560000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5625000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4862000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4423000
CY2021Q4	apls	Lessee Operating Lease Liability Payments Due Year Five And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter	4839000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	25309000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4113000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21196000
CY2020	apls	Implied Cost Of Borrowing Discount Rates ImpliedCostOfBorrowingDiscountRates	0.0791
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3100000
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2100000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	800000
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	38677000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Foreign EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign	-0.052
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	22760000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1845000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-156660000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-72036000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-63988000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-314673000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-118839000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-297127000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-431329000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-224190000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-7580000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-746002000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-343029000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-304707000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	205000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	57000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	147000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1788000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	352000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1845000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	352000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Foreign EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign	-0.066
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-14145000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.019
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-14107000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.041
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-16424000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.054
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	133668000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.179
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	240065000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.699
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	90300000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.296
CY2020	apls	Income Tax Reconciliation Intellectual Property Transfer IncomeTaxReconciliationIntellectualPropertyTransfer	-162000000
CY2020	apls	Effective Income Tax Rate Reconciliation Intellectual Property Transfer EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer	0.472
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	20005000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.026
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	11696000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.034
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	6113000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.020
CY2020	apls	Tax Cuts And Jobs Act Of2017 Change In State Apportionment TaxCutsAndJobsActOf2017ChangeInStateApportionment	93000
CY2019	apls	Tax Cuts And Jobs Act Of2017 Change In State Apportionment TaxCutsAndJobsActOf2017ChangeInStateApportionment	-17000
CY2021	apls	Income Tax Reconciliation Loss On Debt Conversion IncomeTaxReconciliationLossOnDebtConversion	-19548000
CY2021	apls	Effective Income Tax Rate Reconciliation Loss On Debt Conversion EffectiveIncomeTaxRateReconciliationLossOnDebtConversion	-0.026
CY2021	apls	Income Tax Reconciliation Change In Permanent And Other IncomeTaxReconciliationChangeInPermanentAndOther	-731000
CY2021	apls	Effective Income Tax Rate Reconciliation Permanent And Other EffectiveIncomeTaxRateReconciliationPermanentAndOther	0.001
CY2020	apls	Income Tax Reconciliation Change In Permanent And Other IncomeTaxReconciliationChangeInPermanentAndOther	-1234000
CY2020	apls	Effective Income Tax Rate Reconciliation Permanent And Other EffectiveIncomeTaxRateReconciliationPermanentAndOther	0.003
CY2019	apls	Income Tax Reconciliation Change In Permanent And Other IncomeTaxReconciliationChangeInPermanentAndOther	-3758000
CY2019	apls	Effective Income Tax Rate Reconciliation Permanent And Other EffectiveIncomeTaxRateReconciliationPermanentAndOther	0.012
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	352000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1845000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.005
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	180963000
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	162011000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	22404000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11827000
CY2021Q4	apls	Deferred Tax Assets Deferred Interest Expense DeferredTaxAssetsDeferredInterestExpense	3925000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	167160000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	122731000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	39672000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	24992000
CY2021Q4	apls	Deferred Tax Assets Orphan Drug Credits DeferredTaxAssetsOrphanDrugCredits	23678000
CY2020Q4	apls	Deferred Tax Assets Orphan Drug Credits DeferredTaxAssetsOrphanDrugCredits	14372000
CY2021Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	91183000
CY2020Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	68883000
CY2021Q4	apls	Deferred Tax Assets Convertible Debt DeferredTaxAssetsConvertibleDebt	5551000
CY2021Q4	apls	Deferred Tax Asset Lease Liability DeferredTaxAssetLeaseLiability	5029000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5100000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	4520000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	207000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	544665000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	409543000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	69000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	23000
CY2020Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	10473000
CY2021Q4	apls	Deferred Tax Liability Right Of Use Asset DeferredTaxLiabilityRightOfUseAsset	4874000
CY2021Q4	apls	Deferred Tax Liabilities Section481 A Adjustment DeferredTaxLiabilitiesSection481AAdjustment	937000
CY2020Q4	apls	Deferred Tax Liabilities Section481 A Adjustment DeferredTaxLiabilitiesSection481AAdjustment	1935000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5880000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	12431000
CY2021Q4	apls	Net Deferred Tax Assets Before Valuation Allowance NetDeferredTaxAssetsBeforeValuationAllowance	538785000
CY2020Q4	apls	Net Deferred Tax Assets Before Valuation Allowance NetDeferredTaxAssetsBeforeValuationAllowance	397112000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	538785000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	397112000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	141700000
CY2021Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.50
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	75163000
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	Generally, the tax years 2018 through 2020 remain open and subject to examination by the major taxing jurisdictions to which the Company is subject.
CY2021Q4	apls	Estimated Termination Costs And Other Fees EstimatedTerminationCostsAndOtherFees	2300000
CY2021	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	0
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	70667
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45376
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21144
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P48M
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	Options granted to employees on or after December 5, 2013 generally vest in installments of (i) 25% at the one-year anniversary and (ii) in either 36 equal monthly or 12 equal quarterly installments beginning in the thirteenth month after the initial vesting commencement date (as defined) subject to the employee’s continuous service with the Company.
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11736000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.13
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2663000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	48.10
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1064000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	13.82
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	773000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	36.53
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12562000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	24.65
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7699000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	16.24
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	240004000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4863000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	37.95
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-304707000
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	84421000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	51821000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2700000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2900000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4400000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	30.72
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	27.52
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	17.31
CY2021Q4	apls	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodAggregateIntrinsicValue	39900000
CY2020Q4	apls	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodAggregateIntrinsicValue	38000000.0
CY2019Q4	apls	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodAggregateIntrinsicValue	15700000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	53200000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	33600000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	12900000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	105100000
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M29D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-746354000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-344874000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62229000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-8.84
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.59
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.90
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18651000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25415000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10854000
CY2021	dei	Auditor Firm AuditorFirmId	34

Files In Submission

Name	View Source	Status
0001564590-22-007606-index-headers.html	Edgar Link	pending
0001564590-22-007606-index.html	Edgar Link	pending
0001564590-22-007606.txt	Edgar Link	pending
0001564590-22-007606-xbrl.zip	Edgar Link	pending
apls-10k_20211231.htm	Edgar Link	pending
apls-10k_20211231_htm.xml	Edgar Link	completed
apls-20211231.xsd	Edgar Link	pending
apls-20211231_cal.xml	Edgar Link	unprocessable
apls-20211231_def.xml	Edgar Link	unprocessable
apls-20211231_lab.xml	Edgar Link	unprocessable
apls-20211231_pre.xml	Edgar Link	unprocessable
apls-ex1010_257.htm	Edgar Link	pending
apls-ex1029_255.htm	Edgar Link	pending
apls-ex1030_256.htm	Edgar Link	pending
apls-ex211_11.htm	Edgar Link	pending
apls-ex231_9.htm	Edgar Link	pending
apls-ex311_14.htm	Edgar Link	pending
apls-ex312_15.htm	Edgar Link	pending
apls-ex321_10.htm	Edgar Link	pending
apls-ex322_12.htm	Edgar Link	pending
apls-ex44_16.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g3qav3nknoio000001.jpg	Edgar Link	pending
g3qav3nknoio000002.jpg	Edgar Link	pending
gfsxoudqkq03000001.jpg	Edgar Link	pending
gg0b4wbfswa2000001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APLS
Apellis Pharmaceuticals, Inc. Stock $apls

2021 Form 10-K Financial Statement

#000156459022007606 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APLS Apellis Pharmaceuticals, Inc. Stock $apls

2021 Form 10-K Financial Statement

#000156459022007606 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APLS
Apellis Pharmaceuticals, Inc. Stock $apls